Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) EBT (2016 - 2025)

Historic EBT for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to -$62.0 million.

  • Regenxbio's EBT fell 392.14% to -$62.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$178.1 million, marking a year-over-year increase of 2551.16%. This contributed to the annual value of -$227.1 million for FY2024, which is 1386.1% up from last year.
  • Latest data reveals that Regenxbio reported EBT of -$62.0 million as of Q3 2025, which was down 392.14% from -$70.9 million recorded in Q2 2025.
  • Over the past 5 years, Regenxbio's EBT peaked at $307.5 million during Q4 2021, and registered a low of -$76.8 million during Q1 2022.
  • Moreover, its 5-year median value for EBT was -$61.9 million (2023), whereas its average is -$39.8 million.
  • Examining YoY changes over the last 5 years, Regenxbio's EBT showed a top increase of 85925.23% in 2021 and a maximum decrease of 76459.95% in 2021.
  • Quarter analysis of 5 years shows Regenxbio's EBT stood at $307.5 million in 2021, then tumbled by 119.51% to -$60.0 million in 2022, then decreased by 5.11% to -$63.0 million in 2023, then increased by 18.67% to -$51.3 million in 2024, then dropped by 20.85% to -$62.0 million in 2025.
  • Its last three reported values are -$62.0 million in Q3 2025, -$70.9 million for Q2 2025, and $6.1 million during Q1 2025.